Recursion Pharmaceuticals (RXRX) EBIT (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of EBIT data on file, last reported at -$128.5 million in Q1 2026.

• Quarterly EBIT rose 32.85% year-over-year to -$128.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$585.3 million (down 1.96% YoY) and the FY2025 annual result came in at -$648.1 million, down 35.31% from the prior year.
• EBIT fell to -$128.5 million in Q1 2026, from -$108.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$56.0 million in Q1 2022 to a low of -$191.4 million in Q1 2025.
• A 5-year average of -$108.9 million and a median of -$98.9 million in 2023 frame the typical range for EBIT.
• The widest YoY moves for EBIT: up 41.05% in 2025, down 98.64% in 2025.
• Tracing RXRX's EBIT over 5 years: stood at -$61.0 million in 2022, then tumbled by 62.23% to -$98.9 million in 2023, then tumbled by 85.76% to -$183.8 million in 2024, then jumped by 41.05% to -$108.3 million in 2025, then dropped by 18.62% to -$128.5 million in 2026.
• The last three EBIT figures came in at -$128.5 million (Q1 2026), -$108.3 million (Q4 2025), and -$172.2 million (Q3 2025), per Business Quant data.